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Collection of an adequate number of hematopoietic stem cells can be difficult in patients with relapsed or
refractory Hodgkin lymphoma (HL) who are candidates for autologous stem cell transplantation (ASCT).
Plerixafor (AMD3100), an inhibitor of the interaction between stromal cell-derived factor 1 (SDF-1) and
its receptor CXCR4, is an effective hematopoietic stem cell mobilization agent in patients with multiple my-
eloma and non-Hodgkin lymphoma (NHL). This study was undertaken to investigate the efficacy and safety of
hematopoietic stem cell mobilization with plerixafor in patients with HL. Twenty-two patients with HL who
were candidates for ASCTunderwent hematopoietic stem cell mobilization with a combination of granulo-
cyle-colony stimulating factor (G-CSF), 10 mg/kg daily, and plerixafor, 240 mg/kg subcutaneous, 10-11 hours
prior to apheresis. The primary endpoint was the proportion of patients who collected $5  106 CD341
cells/kg. Outcomes were compared to a historical control population of HL patients mobilized with G-CSF
alone. Pharmacokinetic (PK) analysis of plerixafor was performed in a subset of patients. Fifteen patients
(68%) collected $5  106 CD341 cells/kg, and 21 patients (95%) achieved the minimum collection of $2
 106 CD341 cells/kg, in a median 2 apheresis procedures. Both the proportion of patients collecting $5
 106 CD341 cells/kg and the median CD341 cells collected in days 1-2 of apheresis were significantly im-
proved over historical controls. The PK of plerixafor in this patient population was similar to that previously
seen in healthy volunteers. The regimen was generally safe and well tolerated.
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Autologous stem cell transplantation (ASCT) is in-
dicated for patients with Hodgkin lymphoma (HL)
who have primary progressive disease or who relapse af-
ter a chemotherapy-induced complete remission [1-7].
For these patients, as for other patients undergoing au-
tologous transplantation, the number of CD341 cells
collected is a reliable predictor of neutrophil and platelet
engraftment after transplantation. Patients who receive
at least 5  106 CD341 cells/kg have faster recovery of
neutrophils and platelets, and the rate of platelet recov-
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doi:10.1016/j.bbmt.2008.08.011ery may continue to improve with doses .5  106
CD341 cells/kg [8]. Conversely, if\1-2  106 CD341
cells/kg cells are transplanted, patientsmay have delayed
engraftment or graft failure.Unfortunately, collectionof
peripheral blood stem cells (PBSCs) can be difficult in
the HL population [9,10], as these patients usually
have received multiple prior cytotoxic regimens.
Plerixafor (AMD3100) reversibly inhibits the
binding of stromal cell-derived factor 1 (SDF-1), con-
stitutively expressed on bone marrow stromal cells, to
its receptor CXCR4, expressed on CD341 cells. After
a single subcutaneous dose of plerixafor, rapid mobili-
zation of CD341 cells has been observed in both nor-
mal volunteers [11] and in patients with multiple
myeloma (MM) or non-Hodgkin lymphoma (NHL)
[12]. Phase III studies have demonstrated that plerixa-
for combined with granulocyte-colony stimulating
factor (G-CSF) improves PBSC collection compared
to mobilization with G-CSF alone in patients with
MM or NHL [13,14].
This study was undertaken to determine the effi-
cacy and safety of the addition of plerixafor to the1253
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for HL. Results were compared with a historical con-
trol population composed of 98 consecutive patients
with HL who underwent PBSC collection with
G-CSF alone mobilization at Washington University
School of Medicine from 1998 to 2003. In addition,
pharmacokinetic analysis was performed in a subset
of 9 patients following the first dose of plerixafor.
METHODS
Patient Eligibility
Patients with a diagnosis of HL who were candi-
dates for autologous PBSC transplantation were eligi-
ble for this study. Additional eligibility criteria
included: age 18 to 70 years, no more than 3 prior reg-
imens of chemotherapy, receipt of last dose of chemo-
therapy more than 4 weeks before study entry, Eastern
Cooperative Oncology Group (ECOG) performance
status of 0 or 1, white blood cell (WBC) count .3.0
 109/L, absolute neutrophil count (ANC) .1.5 
109/L, platelet count .100  109/L, serum creatinine
#2.2 mg/dL, liver function tests\2 times the upper
limit of normal, adequate cardiac and pulmonary func-
tion, negative for HIV infection. Exclusion criteria
included: failed previous stem cell collection, residual
acute medical condition resulting from prior chemo-
therapy, HL involving the central nervous system,
acute infection or fever, pregnant or lactating female,
actual body weight exceeding 150% of ideal body
weight, history of ventricular arrhythmias, history of
grade $2 paresthesias.
The study protocol was approved by the Human
Research Protection Office at Washington University
School of Medicine. All patients provided written
informed consent.
Investigational Drug
Plerixafor was supplied as a solution of 10 mg/mL
or 20 mg/mL per 1 mL glass ampule. The amount of
study drug administered was calculated based on the
patient’s actual weight. The study drug was stored at
room temperature (15

C to 25

C) in a secure location
accessible only by authorized personnel.
PBSC Mobilization and Transplantation
Each patient was given a subcutaneous injection of
G-CSF 10 mg/kg daily in the morning for 4 days prior
to the first day of apheresis and continuing each morn-
ing just prior to apheresis. On the evening of the fourth
day of G-CSF and each evening prior to apheresis
(10-11 hours prior to the start of apheresis), plerixafor
240 mg/kg was given as a subcutaneous injection.
Venous samples for CBC and FACS analysis were
collected immediately prior to each dose of plerixaforand 10-11 hours after each dose, immediately prior
to apheresis. CD341 cells were enumerated using
standard flow cytometric techniques both in the local
laboratory (Barnes Jewish Hospital, St. Louis, MO)
and in a central reference laboratory (Esoterix, Mem-
phis, TN). Patients returned daily for a morning
dose of G-CSF, the collection of hematopoietic stem
cells, and an evening dose of plerixafor for up to 5 con-
secutive days or until $5  106 CD341 cells/kg had
been collected. Patients underwent a standard 3-blood
volume apheresis procedure on each day of hemato-
poietic stem cell collection. At each visit, patients
were asked about toxicities, and their symptoms were
recorded in the nursing record. Patients returned 24
hours after the last apheresis procedure for a final
laboratory and toxicity assessment. Toxicity data was
collected from the nursing record and transcribed in
the case report forms.
Patients received myeloablative conditioning fol-
lowed by infusion of the G-CSF 1 plerixafor-mobi-
lized cells. The choice of conditioning regimen and
supportive care were left to the discretion of the treat-
ing physicians. Posttransplantation, patients were
monitored for neutrophil and platelet engraftment.
Date of neutrophil engraftment was either the first of
3 consecutive days in which the ANC was .500/mL
or the first day in which the ANC was .1000/mL,
and date of platelet engraftment was the first of 7
days in which the platelet count exceeded 20,000/mL
without transfusion.
Pharmacokinetics
In a subset of 9 patients, blood samples for the de-
termination of plerixafor plasma concentrations were
collected at multiple time points over 10 hours follow-
ing the first dose of plerixafor, with the 10-hour sample
collected just prior to apheresis. Plerixafor concentra-
tions in heparinized plasma were determined using
a validated HPLC-mass spectrometry method (Av-
Tech Laboratories, Kalamazoo, MI). In this method,
internal standard (deuterated plerixafor, 5 ng) was
added to plasma (200 mL) followed by the addition of
ethylenediamine dihydrochloride (2 mg). Plasma pro-
teins were then precipitated by the addition of acetoni-
trile acidified with trifluoroacetic acid (TFA), followed
by vortexing (5 seconds) and microcentrifugation
(12,000  g for 5 minutes). Supernatants were trans-
ferred to clean tubes, 20 mL ethylene glycol was added,
and the samples vortexed, followed by evaporation to
dryness under a stream of nitrogen. Calibration stan-
dards and quality control (QC) samples were prepared
by the addition of plerixafor to blank human plasma
and were processed in the samemanner as patient sam-
ples. Following reconstitution in 0.5% TFA in water,
extracts were analyzed by reverse-phase chromatogra-
phy (C18 column, acetonitrile:water gradient; total
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tion (electrospray interface in positive ion mode).
Validation of this method included assessment of
linearity, within-run and between-run precision and
accuracy, selectivity, long-term (frozen), short-term
(room temperature), autosampler, freeze-thaw, and
processed sample stability, extraction efficiency, carry-
over, and the effect of dilution. The validated calibra-
tion range was from 5-1000 ng/mL and was selected
based on linearity (R2 . .95) and accuracy and preci-
sion criteria for the validation runs. Acceptance criteria
for patient sample runs were based on results for cali-
bration standards and QC samples included in each
run.
Pharmacokinetic parameters were estimated by
noncompartemental methods using WinNonlin
Professional, version 5.2 (Pharsight Corp., Mountain
View, CA). The area under the plasma concentration
time curve (AUC), peak concentration in plasma
(Cmax), time to maximum concentration (Tmax), termi-
nal elimination half-life (t1/2), apparent total systemic
clearance (CL/F, where F represents the fraction of
the dose absorbed), and apparent volume of distribu-
tion (Vz/F) were calculated.
Historical Control Population
The control group is composed of all patients with
HL who were mobilized with G-CSF alone at Wash-
ington University School of Medicine from 1997 to
2003. Information about the control group was col-
lected as part of a comprehensive retrospective study
examining hematopoietic stem cell mobilization out-
comes at our center. The control patients underwent
20 liter exchanges for each apheresis procedure.
Statistical Analysis
All enrolled patients were analyzed for safety and
efficacy. The primary endpoint was the proportion of
patients who collected $5  106 CD341 cells/kg.
The secondary endpoints were the proportion of pa-
tients who collected $2  106 CD341 cells/kg, the
safety of plerixafor in this patient population, the num-
ber of days of apheresis required to obtain $5  106
CD341 cells/kg, the change in the number of
CD341 cells circulating in the peripheral blood from
time 0 to 10-11 hours after a dose of plerixafor, the
time to engraftment of neutrophils and platelets, and
graft durability at 3, 6, and 12 months after stem cell
transplantation. One patient underwent 2 mobiliza-
tions with G-CSF1 plerixafor because the first hema-
topoietic stem cell product was discarded for bacterial
contamination. Only the data from that patient’s first
collection was included in the evaluation of the
primary and secondary endpoints.
CD341 cells counts as reported by the local labo-
ratory were used to calculate the primary and second-ary endpoints and in comparison with historical
controls. Adverse events were categorized as mild
(awareness of sign or symptoms, but easily tolerated),
moderate (discomfort enough to cause interference
with usual activity), or severe (incapacitating with in-
ability to work or do usual activity). Descriptive statis-
tics were used to summarize CD341 cell collections,
number of days of apheresis, circulating CD341 cells,
and days to neutrophil and platelet engraftment. A
power justification was conducted using c2 test based
on a binomial distribution. Compared with the histor-
ical success rate of 15% (percent of patients reaching
5  106 CD341 cells/kg), a minimum of 16 evaluable
patients would allow us, with 80% power and at a
1-sided .05 significance level, to detect a minimal
25% improvement in success rate (eg, 15% versus
40%). Therefore, our study was adequately powered.
RESULTS
Patient Characteristics
Twenty-two patients with relapsed or refractory
HL were enrolled in this study and underwent hema-
topoietic stem cell mobilization with G-CSF1 plerix-
afor. Patient characteristics are summarized in Table
1. Ninety-one percent of patients had received 2 or
more prior chemotherapy regimens. Seventy-three
percent of patients were in second complete remission
(CR) or partial remission (PR); 14% in first CR or PR;
and 14% had active or refractory disease at the time of
transplant.
Response to Plerixafor
CD341 cell collection
Fifteen patients (68%) met the primary endpoint
and achieved a collection of $5  106 CD341 cells/
kg, and 21 patients (95%) collected $2  106
CD341 cells/kg. The median collection was 6.6 
106 CD341 cells/kg (range: 0.9-10.4  106). Mean
CD341 cell collection was higher in patients under
the age of 45 years (n 5 16, 7.2  106 CD341 cells/
kg) than in patients over the age of 45 (n 5 6, 4.3 
106 CD341 cells/kg) (P5 .01). These results were de-
termined using local laboratory data. Apheresis sam-
ples from 20 patients were received in the central
laboratory for CD341 cell enumeration. Based on
analysis from the central laboratory, 13 of 20 patients
(65%) achieved a collection of $5  106 CD341
cells/kg, 19 of 20 patients (95%) collected $2  106
CD341 cells/kg, and the median collection was 6.9
 106 CD341 cells/kg (range: 1.3-15.1  106).
The only patient who failed to collect $2  106
CD341 cells/kg was a 54-year-old man who had
been treated in the 12 months prior to hematopoietic
stem cell mobilization with the Stanford 5 regimen,
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and cisplatin (DHAP). His circulating CD341 cell
count increased from 2 to 6 cells/mL after the first
dose of plerixafor, and he collected a total of 0.94 
106 CD341 cells/kg in 3 apheresis procedures.
The median number of apheresis procedures per-
formed per patient was 2 (range: 1-5). Per the local lab-
oratory data, 13 of 15 patients who collected$5 106
CD341 cells/kg achieved that target in 1 (n5 7) or 2 (n
5 6) apheresis procedures (Figure 1). Two other pa-
tients underwent 3 apheresis procedures to collect
$5  106 CD341 cells/kg. In the study population
as a whole, the median collection in 2 apheresis proce-
dures was 6.2 106 CD341 cells/kg (range: 0.6-10.4
106 CD341 cells/kg).
One patient underwent 2 mobilizations with
G-CSF1 plerixafor because the first stem cell product
was contaminated with bacteria and had to be
Table 1. Patient Characteristics of Study Patients, Mobilized
with G-CSF + Plerixafor, (N 5 22) and Historical Controls
Mobilized with G-CSF Alone (N 5 98)
G-CSF + Plerixafor
n (%)
G-CSF
n (%) P-Value
Mean age ± SD (years) 32.7 ± 11.9 32.9 ± 12.5 .67
M/F 9/13 (41/59) 57/41 (58/42) .16
Race
Caucasian 22 (100) 86 (88) .33
Black 9 (9)
Other 3 (3)
Number of prior
chemotherapy regimens*
1 2 (9) 16 (17) .35
2 18 (82) 56 (60)
3 2 (9) 19 (20)
$4 2 (2)
Prior radiotherapy† 9 (41) 44 (48) .81
*Data available for N 5 93 of control (G-CSF) patients.
†Data available for N 5 92 of control (G-CSF) patients.
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Figure 1. Number of apheresis days to reach cell count targets of 2 
106 CD341 cells/kg and 5  106 CD341 cells/kg after treatment with
G-CSF 1 plerixafor.discarded. She collected 4.9  106 CD341 cells/kg in
4 apheresis procedures with the first mobilization.
One month later she underwent a second mobilization
with G-CSF 1 plerixafor and collected 1.4  106
CD341 cells/kg in 4 apheresis procedures. She subse-
quently had additional CD341 cells collected after
a chemomobilization, and the chemomobilized and
plerixafor-mobilized stem cells were combined and in-
fused after conditioning with high-dose chemother-
apy. Only the results of the first hematopoietic stem
cell collection were included in the analysis of the
primary endpoint.
The stem cell collection outcomes for patients
enrolled in this study were compared with those of
a historical control group composed of 98 consecutive
patients withHLwho underwentG-CSFmobilization
and PBSC collection atWashingtonUniversity School
of Medicine from 1998 to 2003. The characteristics of
the control population are not statistically different
than those of the study patients (Table 1). In the con-
trol population, 22 patients (22%) did not achieve the
minimum collection of 2  106 CD341 cells/kg in
fewer than 5 apheresis procedures, and only 15 patients
(15%) achieved a collection greater than 5  106
CD341 cells/kg. The mean number of apheresis
procedures was 2.9. Compared to these historical out-
comes, mobilization with G-CSF 1 plerixafor pro-
duced statistically significant improvement in the
proportion of patients collecting $5  106 CD341
cells/kg and in the median number of CD341 cells
collected in days 1 and 2 of apheresis (Table 2).
Circulating CD341 cell count
For each patient treated with plerixafor, the pe-
ripheral blood CD341 cell count was analyzed by
flow cytometry immediately prior to the first dose of
plerixafor and 10-11 hours later, prior to apheresis
(Figure 2). At baseline, the median CD341 count
was 13 cells/mL (range: 0-74), and after plerixafor the
median CD341 count was 40 cells/mL (range:
6-156). There was a median 3.2-fold increase in the
peripheral CD341 cell count after plerixafor (range:
1.7-5.7). All patients with a pre-plerixafor CD341
Table 2. Mobilization with G-CSF + Plerixafor Compared to
Historical Controls Mobilized with G-CSF Alone*
G-CSF + Plerixafor G-CSF P-Value
Total patients 22 98
Number collecting $5 
106 CD34+ cells/kg
15 (68%) 15 (15%) <.001
Number collecting $2 
106 CD34+ cells/kg
21 (95%) 76 (78%) .071
Median CD34+ cells
collected, days 1-2
6.2 x 106/kg 3.0 x 106/kg <.001
Mean number
of aphereses
2.5 2.9 NS
NS indicates nonsignificant.
*Data from local laboratory.
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Figure 2. Peripheral blood CD341 cell count of each patient, pre- and postplerixafor after 4 days of G-CSF treatment.cell count .10 cells/mL (n 5 12) met the collection
goal of $5  106 CD341 cells/kg, whereas only 2 of
10 patients with a preplerixafor CD341 cell count
#10 cells/mL met the collection goal.
The CD341 cell count just prior to plerixafor
(after 4 days of G-CSF) correlated with both the day
1 CD341 cell collection (Figure 3a) and the total col-
lection (Figure 3c). Similarly, the CD341 cell count
10-11 hours after plerixafor correlated with both the
day 1 CD341 cell collection (Figure 3b) and the total
collection (Figure 3d). There was no correlation
between the fold increase in the CD341 cell count
after plerixafor and the number of CD341 cells col-
lected (data not shown).
Engraftment of plerixafor mobilized cells
Twenty-one patients were transplanted with
G-CSF 1 plerixafor mobilized cells following treat-
ment with the BEAM preparative regimen (carmus-
tine, etoposide, cytarabine, and melphalan). All had
prompt engraftment, with median neutrophil engraft-
ment at day 9 (range: 8-14) and median platelet
engraftment at day 119 (range: 11-29). At 12 months
posttransplant, all 21 patients had stable engraftment,
with no graft failures reported.
Toxicity
Adverse events attributed to plerixafor are summa-
rized in Table 3. In general, plerixafor was well toler-
ated, and there were no drug-related serious adverse
events. Overall, 14 patients (64%) experienced at least
1 toxicity possibly, probably, or definitely related to
plerixafor, and all of the drug-related adverse events
were consistent with the known plerixafor safety pro-file. Injection site erythema was the most common ad-
verse event, occurring in 13 patients (59%). The
injection site reaction was mild for all of these patients
except 1, who reported a severe burning sensation and
moderate erythema that lasted for 5 minutes after the
plerixafor injection. No patient required treatment
for the injection site reaction. The noncutaneous tox-
icities associated with plerixafor were gastrointestinal
in nature and were experienced by 5 patients (23%).
Among these patients, 2 were treated with an anti-
emetic for mild nausea and vomiting, 1 patient was
treated for moderate diarrhea, and 1 patient was
treated for moderate abdominal pain. The other pa-
tient had mild abdominal cramping and mild diarrhea
and did not require any treatment. No adverse events
related to the study treatment occurred in the time
period after the first pretransplant chemotherapy.
With respect to laboratory data, there were mean
increases from baseline for WBC and neutrophils at
24 hours, as expected. There were mean decreases
from baseline for hemoglobin and platelet count after
24 hours. There were no unexpected changes in chem-
istry findings.
Pharmacokinetics
Plerixafor was rapidly absorbed following subcuta-
neous injection, and peak plasma concentrations
(median 5 750 ng/mL) occurred approximately 30
minutes after administration (Table 4). Plerixafor
had a small apparent volume of distribution, with ame-
dian value of 25.9 L, indicating that it is primarily con-
fined to slightly less than the whole body fluid
compartment. Plerixaforwas rapidly clearedwith ame-
dian terminal half-life of 3.6 hours. The PK profile in
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Figure 3. Correlations between circulating CD341 cell count and CD341 cell collection. (A) CD341 cell count just prior to plerixafor (after 4 days of
G-CSF) versus day 1 CD341 cell collection; (B) CD341 cell count 10-11 hours after plerixafor versus day 1 CD341 cell collection; (C) CD341 cell count
just prior to plerixafor (after 4 days of G-CSF) versus total CD341 cell collection; and (D) CD341 cell count 10-11 hours after plerixafor versus total
CD341 cell collection.HL patients pretreated with G-CSF (Figure 4) was
similar to the profiles previously observed in healthy
volunteers who received plerixafor, 240 mg/kg, alone
[15] and in NHL and MM patients treated with
G-CSF 1 plerixafor [16].
DISCUSSION
G-CSF is currently the agent most commonly used
for hematopoietic stem cell mobilization, because of
its potency and relative safety. However, a significant
Table 3. Adverse Events Possibly, Probably, or Definitely
Related to Plerixafor
Number of Patients (N 5 22)
Adverse Event Mild Moderate Severe
Injection site erythema or irritation 12 0 1
Diarrhea 2 1
Nausea 2
Vomiting 1
Abdominal pain or discomfort 1 1minority of patients fail to collect an adequate number
of hematopoietic stem cells with standard G-CSF
mobilization, often resulting from advanced age or
extensive prior chemotherapy [17-19]. Plerixafor is
a promising new mobilizing agent that has demon-
strated efficacy in patients with NHL and MM under-
going autologous stem cell mobilization. In a Phase I
study in 13 patients with MM or NHL, a mean
6-fold increase in the peripheral CD341 cell count
was observed 6 hours after an injection of plerixafor,
160 or 240 mg/kg [12]. Flomenberg et al. [20] subse-
quently used a combination of G-CSF and plerixafor
for autologous stem cell mobilization in 25 patients
with MM or NHL. Each patient underwent 2 mobili-
zations: 1 with G-CSF alone and 1 with the plerixafor
combination. In all cases, G-CSF 1 plerixafor mobi-
lized more CD341 cells per leukapheresis than did
G-CSF alone, and 9 patients who failed to collect $2
 106 CD341 cells/kg with G-CSF did achieve that
target with G-CSF 1 plerixafor. In addition, G-CSF
1 plerixafor mobilization was associated with fewer
leukaphereses and a greater likelihood of collecting
$5  106 CD341 cells/kg. The combination of
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Cmax (mg/mL) Tmax (h) t1/2 (h) CL/F (L/h) Vz/F (mL) AUC0-10 (ng  h/mL) AUC0-24 (ng  h/mL)
Median 0.75 0.5 3.6 4.9 25.9 3,501 3,884
Range 0.62-1.16 0.3-1.3 2.4-4.3 3.0-9.5 10.6-41.7 2646-5042 2877-5307
Cmax indidates maximum concentration; Tmax, time to maximum concentration; t1/2, half-life; CL/F, systemic clearance; Vz/F, volume of distribution; AUC,
area under the plasma concentration time curve.G-CSF and plerixafor also has been demonstrated to
mobilize the majority of patients with lymphoma or
MMwho have failed prior mobilization with cytokines
and/or chemotherapy [21,22].
A Phase III trial randomized 298 patients with
NHL to mobilization with G-CSF 1 plerixafor or
G-CSF1 placebo [14]. The primary endpoint, collec-
tion of$5 106 CD341 cells/kg in#4 apheresis days,
was achieved by 59% of patients in the plerixafor
group, versus 20% in the G-CSF alone group (P\
.0001). In addition, fewer patients in the plerixafor
group failed to collect at least 2  106 CD341 cells/
kg (13% versus 53%, P\ .0001). A randomized, pla-
cebo-controlled study inMMpatients showed a similar
benefit to the combination of G-CSF and plerixafor
[13]. In that trial, 72% of myeloma patients mobilized
with G-CSF 1 plerixafor collected $6  106 CD341
cells/kg in 2 or fewer apheresis compared to 34% of
patients mobilized with G-CSF alone (P \ .0001).
Over half of patients given G-CSF 1 plerixafor
reached the target collection in 1 day of apheresis.
Our results expand the clinical experience with
plerixafor to include patients with relapsed or refrac-
toryHL, for whomASCT is a potentially curative pro-
cedure. In our experience, 20% to 30% of this patient
population does not collect sufficient hematopoietic
stem cells with G-CSF mobilization to proceed with
a stem cell transplant. In addition, only 15% of our his-
torical population collected.5 106 CD341 cells/kg,
a target stem cell dose associated with faster platelet re-
covery. In contrast, with the combination of G-CSF1plerixafor, 21 of 22 patients achieved the minimum he-
matopoietic stem cell collection, and 15 of 22 collected
$5  106 CD341 cells/kg, a significant improvement
over the historical control group. Although the mean
number of aphereses performed per patient did not
differ significantly between the historical control
group and the study group mobilized with G-CSF 1
plerixafor, the combinationwas associatedwith a statis-
tically significant improvement in the number of he-
matopoietic stem cells collected in the first 2 days of
apheresis. Collection of more stem cells in fewer
apheresis procedures has many potential advantages,
including a decrease in procedure-related adverse re-
actions, less utilization of costly personnel and blood
bank resources, and improved transplant outcomes
from infusion of a higher stem cell dose. Potential
disadvantages of the addition of plerixafor to G-CSF
mobilization include the expense of plerixafor, possi-
ble side effects, and the inconvenience of giving an
injection the evening prior to apheresis.
This study included measurement of each patient’s
peripheral CD341 cell count immediately prior to the
first dose of plerixafor (after 4 days of G-CSF) and
10-11 hours after plerixafor. There was marked inter-
patient variation in the peripheral CD341 cell counts
at both of these time points, with a median 3.2-fold
increase in circulating CD341 cells after plerixafor.
Notably, both the pre- and postplerixafor CD341
cell counts correlated significantly with the subsequent
hematopoietic stem cell collection, suggesting that
analysis of the peripheral CD341 cell count prior toTime (hours)
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Figure 4. Mean plerixafor plasma concentrations over time in HL patients following a subcutaneous 240 mg/kg dose (shown on a semilog scale). Error
bars are standard deviations.
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a patient will have a successful stem cell collection after
G-CSF 1 plerixafor mobilization.
Because the CXCR4 receptor on CD341 cells
plays a role in hematopoietic stem cell homing to
bone marrow, there has been concern that stem cells
mobilized with plerixafor may exhibit poor engraft-
ment. However, studies in animal models have demon-
strated that stem cell engraftment is not affected by
mobilization with plerixafor [23,24]. In fact, bonemar-
row repopulation may actually be improved with pler-
ixafor mobilization [25,26]. The reliable engraftment
capacity of hematopoietic stem cells mobilized with
plerixafor has been demonstrated in the clinical trials
reported to date, and our results confirm those
findings. All of the HL patients transplanted with
G-CSF 1 plerixafor mobilized cells had prompt and
durable engraftment.
This study includes the first published report of the
pharmacokinetics of plerixafor in cancer patients. Pler-
ixafor was rapidly absorbed, with peak plasma concen-
trations occurring approximately 30 minutes after
subcutaneous injection, and had a median elimination
half-life of 3.6 hours. The pharmacokinetic profile of
plerixafor reported in this study population is consis-
tent with those previously observed in healthy volun-
teers in the absence of G-CSF [15] and in patients
with MM and NHL [16].
In conclusion, our study demonstrates that G-CSF
1 plerixafor is an effective andwell-toleratedmobiliza-
tion regimen in patients with HL undergoing autolo-
gous stem cell collection. When compared to
historical outcomes with G-CSF alone mobilization,
the combination of G-CSF 1 plerixafor is associated
with a significant improvement in the proportion of
patients who collect $5  106 CD341 cells/kg and in
the number of CD341 cells collected in the first 2
days of apheresis. Importantly, mobilization with pler-
ixafor enables more HL patients to collect the mini-
mum number of CD341 cells required for stem cell
transplantation, increasing the proportion of patients
who can proceed with that potentially curative therapy.
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